Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicomorphine SCHEMBL680036 | 1.00 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL26237 | 1.00 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL29349768 | 1.00 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL1649977 | 0.99 | OPRD1 (0.68) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL395672 | 0.99 | OPRD1 (0.68) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicocodine SCHEMBL1023092 | 0.94 | OPRM1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicocodine SCHEMBL159020 | 0.94 | OPRM1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicocodine SCHEMBL29531263 | 0.94 | OPRM1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| SCHEMBL27496008 | 0.91 | OPRD1 (0.66) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| SCHEMBL1556900 | 0.91 | OPRD1 (0.82) | OPRD1OPRM1OPRK1ADRB1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3064199-B1 | ABUSE-DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | BUZZZ PHARMACEUTICALS LTD (IE) | 2023-12-20 | — | — | EP | claimed |
| EP-3405179-B1 | CONTROL OF THE RELEASE OF WATER FROM A SOLID COMPOSITION CONTAINING WATER | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2023-08-09 | — | — | EP | claimed |
| EP-3528804-B1 | CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND OPIOID AGONISTS AND/OR ANTAGONISTS | APIRX PHARMACEUTICAL USA LLC (US) | 2023-07-26 | — | — | EP | claimed |
| EP-3313407-B1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2023-07-19 | — | — | EP | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114601834-A | Use of mitochondrial fission inhibitors and combinations comprising the same | 复旦大学 | 2022-06-10 | — | — | CN | claimed |
| CN-109553565-B | Two new alkaloids, preparation method thereof and application thereof in preparation of MRSA-resistant antibacterial agent | 华南农业大学 | 2022-04-05 | — | — | CN | claimed |
| CN-117772131-A | Clay mineral-based carbon-silicon oxide nanocomposite and preparation method and application thereof | 中国科学院广州地球化学研究所 | 2024-03-29 | — | — | CN | disclosed |
| EP-3405179-B1 | CONTROL OF THE RELEASE OF WATER FROM A SOLID COMPOSITION CONTAINING WATER | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2023-08-09 | — | — | EP | disclosed |
| CN-116018131-A | Fast orodispersible tablet with inner cavity | 阿普雷奇亚制药有限责任公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115928318-A | Preparation method of antibacterial and antiviral packaging material and packaging material using same | 华南农业大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115942979-A | MGLUR5 antagonist, marvorexant, for use in therapy to reduce opioid use | 诺华股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-1765303-B2 | ORAL TABLET SAFEGUARDED AGAINST ABUSE | GRUENENTHAL GMBH (DE) | 2022-11-23 | — | — | EP | disclosed |
| CN-111132666-B | Composition for delivering physiologically active ingredients to blood vessels | 雷莫内克斯生物制药有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-111632041-B | Abuse resistant pharmaceutical composition | 瑞克欧盖恩斯维尔有限责任公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-115135323-A | Pharmaceutical composition | 深圳市药欣生物科技有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114601834-A | Use of mitochondrial fission inhibitors and combinations comprising the same | 复旦大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-109689058-B | Treatment and prevention of sleep disorders | 普渡制药公司 | 2022-03-22 | — | — | CN | disclosed |